Gilead Sciences, Inc [GILD] stock prices are down -0.32% to $117.99 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The GILD shares have lost -2.06% over the last week, with a monthly amount glided 9.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Gilead Sciences, Inc [NASDAQ: GILD] stock has seen the most recent analyst activity on August 08, 2025, when Truist upgraded its rating to a Buy but kept the price target unchanged to $127 for it. Previously, Needham upgraded its rating to Buy on July 25, 2025, and kept the price target unchanged to $133. Oppenheimer reiterated its Outperform rating and increased its price target to $132 on March 04, 2025. Deutsche Bank upgraded its rating to a Buy but $120 remained the price target by the analyst firm on February 18, 2025. DZ Bank upgraded its rating to Buy for this stock on February 13, 2025, but kept the price target unchanged to $108. In a note dated January 10, 2025, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $87 to $113.
The stock price of Gilead Sciences, Inc [GILD] has been fluctuating between $72.89 and $121.83 over the past year. Currently, Wall Street analysts expect the stock to reach $126.14 within the next 12 months. Gilead Sciences, Inc [NASDAQ: GILD] shares were valued at $117.99 at the most recent close of the market. An investor can expect a potential return of 6.91% based on the average GILD price forecast.
Analyzing the GILD fundamentals
The Gilead Sciences, Inc [NASDAQ:GILD] reported sales of 28.80B for trailing twelve months, representing a surge of 1.64%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.28%, Pretax Profit Margin comes in at 0.25%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.33 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 117.43 points at the first support level, and at 116.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 118.96, and for the 2nd resistance point, it is at 119.93.
Ratios To Look Out For
It’s worth pointing out that Gilead Sciences, Inc [NASDAQ:GILD]’s Current Ratio is 1.32. On the other hand, the Quick Ratio is 1.15, and the Cash Ratio is 0.46. Considering the valuation of this stock, the price to sales ratio is 5.08, the price to book ratio is 7.45 and price to earnings (TTM) ratio is 23.47.
Transactions by insiders
Recent insider trading involved Mercier Johanna, Chief Commercial Officer, that happened on Aug 15 ’25 when 28000.0 shares were sold. Chief Financial Officer, Dickinson Andrew D completed a deal on Aug 15 ’25 to sell 2500.0 shares. Meanwhile, Officer ANDREW DICKINSON bought 2500.0 shares on Aug 15 ’25.
